




## Product Introduction

### Temozolomide

Temozolomide is a DNA damage inducer.

#### Technical Data:

<b>Molecular Weight (MW):</b>	194.15	
<b>Formula:</b>	C <sub>6</sub> H <sub>6</sub> N <sub>6</sub> O <sub>2</sub>	
<b>Solubility (25°C)</b>	DMSO 39 mg/mL	
<b>* &lt;1 mg/ml means slightly soluble or insoluble:</b>	Water 5 mg/mL	
	Ethanol <1 mg/mL	
<b>Purity:</b>	>98%	
<b>Storage:</b>	3 years -20°C Powder 6 months -80°C in DMSO	
<b>CAS No.:</b>	85622-93-1	

#### Biological Activity

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in S/G2-M phases. Methazolastone induces a similar amount of DNA ALS which is also repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. Methazolastone induces a similar amount of DNA ALS which is also repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. [1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and decreases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100  $\mu$ M or 200  $\mu$ M treatment; only 400  $\mu$ M methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1] Methazolastone is a second-generation alkylating agent.

## References

- [1] Catapano CV, et al. *Cancer Res.* 1987, 47(18), 4884-4889.
- [2] Sun S, et al. *J Neurooncol.* 2012.
- [3] Bauer M, et al. *PLoS One.* 2012, 7(6):e39956.
- [4] Wong ST, et al. *Anticancer Res.* 2012, 32(7), 2835-2841.
- [5] Lin CJ, et al. *PLoS One.* 2012, 7(6), e38706.
- [6] Gori JL, et al. *Cancer Gene Ther.* 2012.



Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.